Company / SG&A Expense
BioMarin Pharmaceutical SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$1.2B
FY2025
5-year range
$759.4M / $1.2B
FY2021-FY2025
Trend
+14.3%
vs FY2024
Sector context
#23 of 213
Health Care
What the data says
BioMarin Pharmaceutical's sg&a expense of $1.2B is higher than 89% of companies in the Health Care sector (FY2025). SG&A Expense has increased for 9 consecutive years, from $477M in FY2016 to $1.2B in FY2025.
Based on SEC 10-K filings.
$1.2B in FY2025 with a 5-year CAGR of +9.3%. Top quartile in the Health Care sector.
Increased from $892M to $1.2B over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +11.9%
- 5-Year CAGR
- +9.3%
- 10-Year CAGR
- -
Sector benchmark
Bottom 11% in Health CareTop 89% of 213This company $1.2B Sector average $722.3M
▼
+59.6% above sector average
Key checks
Key Insights
- BioMarin Pharmaceutical's sg&a expense has grown for 9 consecutive years.
- 5-year CAGR of +9.3%, indicating consistent growth.
- In FY2025, sg&a expense increased 14.3% year-over-year.
- Ranks #23 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.2B | +14.3% |
| FY2024 | $1.0B | +13.1% |
| FY2023 | $892.4M | +8.4% |
| FY2022 | $823.2M | +8.4% |
| FY2021 | $759.4M | +2.9% |
| FY2020 | $737.7M | +8.3% |
| FY2019 | $680.9M | +12.7% |
| FY2018 | $604.4M | +9.0% |
| FY2017 | $554.3M | +16.3% |
| FY2016 | $476.6M | +18.5% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026